This article is more than 5 years old. Information may no longer be current.
Use of VITACORA-19 showed good validity, reliability among patients with psoriatic arthritis
Click Here to Manage Email Alerts
The VITACORA-19 showed good validity, reliability and sensitivity to change in measuring health-related quality of life in patients with psoriatic arthritis, according to study results.
In a longitudinal, multicenter study, researchers tested the validity content, internal consistency, test-retest reliability, known groups/convergent validity and sensitivity to change of the VITACORA-19 among 323 patients who also completed the EuroQol 5-dimensional questionnaire (EQ-5D) and a health status transition item. Patients were separated into three groups: patients with psoriatic arthritis (PsA, group A); patients with arthritis without psoriatic aspect, patients with arthrosis and patients with dermatitis (group B); and healthy controls (group C).
Study results showed 94.7% of patients with PsA found the questionnaire to be easy or very easy to answer. The researchers found Cronbach’s alpha coefficient and interclass correlation coefficients exceeded 0.90.
Patients in group C had better health-related quality of life, followed by group B and group A, according to the researchers. Significant correlations were found between VITACORA-19 scores and PsA disease activity, EQ-5D and perceived health state, with patients with better health state receiving higher scores.
Disclosure: The research was supported by a grant from Pfizer.
Click Here to Manage Email Alerts